Prograf + Tacrolimus Hexal
ApprovedCompleted 1 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Pharmacokinetics Study in de Novo Kidney Transplantation
Conditions
Pharmacokinetics Study in de Novo Kidney Transplantation
Trial Timeline
Oct 17, 2012 → Aug 20, 2015
NCT ID
NCT01649427About Prograf + Tacrolimus Hexal
Prograf + Tacrolimus Hexal is a approved stage product being developed by Novartis for Pharmacokinetics Study in de Novo Kidney Transplantation. The current trial status is completed. This product is registered under clinical trial identifier NCT01649427. Target conditions include Pharmacokinetics Study in de Novo Kidney Transplantation.
What happened to similar drugs?
4 of 4 similar drugs in Pharmacokinetics Study in de Novo Kidney Transplantation were approved
Approved (4) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01649427 | Approved | Completed |
Competing Products
20 competing products in Pharmacokinetics Study in de Novo Kidney Transplantation